Search

Your search keyword '"Coiffier, Bertrand"' showing total 1,651 results
Start Over Author "Coiffier, Bertrand"
1,651 results on '"Coiffier, Bertrand"'

1. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Author

Sharman, Jeff, Coutre, Steven, Furman, Richard, Cheson, Bruce, Pagel, John, Hillmen, Peter, Barrientos, Jacqueline, Zelenetz, Andrew, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, Stilgenbauer, Stephan, OBrien, Susan, and Kipps, Thomas

Subjects
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Double-Blind Method, Drug Administration Schedule, Europe, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Progression-Free Survival, Purines, Quinazolinones, Recurrence, Rituximab, Time Factors, United States
Abstract

PURPOSE: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. PATIENTS AND METHODS: Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. RESULTS: The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. CONCLUSION: IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.

Published
2019

2. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Author

Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, and O'Brien, Susan M

Subjects
Cancer, Lymphoma, Clinical Research, Clinical Trials and Supportive Activities, Hematology, Patient Safety, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Kidney Diseases, Leukemia, Lymphocytic, Chronic, B-Cell, Lymph Nodes, Male, Middle Aged, Phosphoinositide-3 Kinase Inhibitors, Purines, Quinazolinones, Recurrence, Rituximab, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population.MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. The primary end point was progression-free survival. At the first prespecified interim analysis, the study was stopped early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy.ResultsThe median progression-free survival was 5.5 months in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P

Published
2014

3. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Author

Ogura, Michinori, Sancho, Juan Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Lennard, Anne, Mariz, José, Ilyin, Nikolai, Jurczak, Wojciech, Lopez Martinez, Aurelio, Samoilova, Olga, Zhavrid, Edvard, Yañez Ruiz, Eduardo, Trneny, Marek, Popplewell, Leslie, Coiffier, Bertrand, Buske, Christian, Kim, Won-Seog, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, and Kwak, Larry W

Published
2018
Full Text
View/download PDF

4. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Author

Federico, Massimo, Caballero Barrigón, María Dolores, Marcheselli, Luigi, Tarantino, Vittoria, Manni, Martina, Sarkozy, Clementine, Alonso-Álvarez, Sara, Wondergem, Marielle, Cartron, Guillaume, Lopez-Guillermo, Armando, Issa, Djamila, Morschhauser, Franck, Alcoceba, Miguel, Kimby, Eva, Rusconi, Chiara, Chamuleau, Martine, Holte, Harald, Lockmer, Sandra, Montoto, Silvia, Gomes da Silva, Maria, Aurer, Igor, Zucca, Emanuele, Paszkiewicz-Kozik, Ewa, Minoia, Carla, Skrypets, Tetiana, Blaker, Yngvild Nuvin, Salles, Gilles, and Coiffier, Bertrand

Published
2018
Full Text
View/download PDF

6. A MALT lymphoma prognostic index

Author

Thieblemont, Catherine, Cascione, Luciano, Conconi, Annarita, Kiesewetter, Barbara, Raderer, Markus, Gaidano, Gianluca, Martelli, Maurizio, Laszlo, Daniele, Coiffier, Bertrand, Lopez Guillermo, Armando, Torri, Valter, Cavalli, Franco, Johnson, Peter W., and Zucca, Emanuele

Published
2017
Full Text
View/download PDF

7. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Author

Kim, Won Seog, Buske, Christian, Ogura, Michinori, Jurczak, Wojciech, Sancho, Juan-Manuel, Zhavrid, Edvard, Kim, Jin Seok, Hernández-Rivas, José-Ángel, Prokharau, Aliaksandr, Vasilica, Mariana, Nagarkar, Rajinish, Osmanov, Dzhelil, Kwak, Larry W, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, and Coiffier, Bertrand

Published
2017
Full Text
View/download PDF

8. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Author

Zelenetz, Andrew D, Barrientos, Jacqueline C, Brown, Jennifer R, Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S, Robak, Tadeusz, Sharman, Jeff P, Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H, Dreiling, Lyndah K, Kim, Yeonhee, Stilgenbauer, Stephan, and Hillmen, Peter

Published
2017
Full Text
View/download PDF

9. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

Author

Peyrade, Frédéric, Bologna, Serge, Delwail, Vincent, Emile, Jean François, Pascal, Laurent, Fermé, Christophe, Schiano, Jean-Marc, Coiffier, Bertrand, Corront, Bernadette, Farhat, Hassan, Fruchart, Christophe, Ghesquieres, Herve, Macro, Margaret, Tilly, Hervé, Choufi, Bachra, Delarue, Richard, Fitoussi, Olivier, Gabarre, Jean, Haioun, Corinne, and Jardin, Fabrice

Published
2017
Full Text
View/download PDF

11. Supplementary Table 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Mareschal, Sylvain, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Maingonnat, Catherine, primary, Jais, Jean-Philippe, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Molina, Thierry J., primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Brière, Josette, primary, Petrella, Tony, primary, Canioni, Danielle, primary, Fabiani, Bettina, primary, Coiffier, Bertrand, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, Bosly, André, primary, André, Marc, primary, Ketterer, Nicolas, primary, Salles, Gilles, primary, Tilly, Hervé, primary, Leroy, Karen, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Tables 1 - 2, Figure 1 from A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Author

Ribrag, Vincent, primary, Dupuis, Jehan, primary, Tilly, Herve, primary, Morschhauser, Franck, primary, Laine, Fabrice, primary, Houot, Roch, primary, Haioun, Corinne, primary, Copie, Christiane, primary, Varga, Andrea, primary, Lambert, John, primary, Hatteville, Laurence, primary, Ziti-Ljajic, Samira, primary, Caron, Anne, primary, Payrard, Sandrine, primary, and Coiffier, Bertrand, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 4 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Methods from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

21. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Author

Ribrag, Vincent, Koscielny, Serge, Bosq, Jacques, Leguay, Thibaut, Casasnovas, Olivier, Fornecker, Luc-Mathieu, Recher, Christian, Ghesquieres, Hervé, Morschhauser, Franck, Girault, Stéphane, Gouill, Steven Le, Ojeda-Uribe, Mario, Mariette, Clara, Cornillon, Jerome, Cartron, Guillaume, Verge, Veronique, Chassagne-Clément, Catherine, Dombret, Hervé, Coiffier, Bertrand, Lamy, Thierry, Tilly, Hervé, and Salles, Gilles

Published
2016
Full Text
View/download PDF

22. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

Author

Dittrich, Christian, Kosty, Michael, Jezdic, Svetlana, Pyle, Doug, Berardi, Rossana, Bergh, Jonas, El-Saghir, Nagi, Lotz, Jean-Pierre, Österlund, Pia, Pavlidis, Nicholas, Purkalne, Gunta, Awada, Ahmad, Banerjee, Susana, Bhatia, Smita, Bogaerts, Jan, Buckner, Jan, Cardoso, Fatima, Casali, Paolo, Chu, Edward, Close, Julia Lee, Coiffier, Bertrand, Connolly, Roisin, Coupland, Sarah, De Petris, Luigi, De Santis, Maria, de Vries, Elisabeth G.E., Dizon, Don S., Duff, Jennifer, Duska, Linda R., Eniu, Alexandru, Ernstoff, Marc, Felip, Enriqueta, Fey, Martin F., Gilbert, Jill, Girard, Nicolas, Glaudemans, Andor W.J.M., Gopalan, Priya K., Grothey, Axel, Hahn, Stephen M., Hanna, Diana, Herold, Christian, Herrstedt, Jørn, Homicsko, Krisztian, Jones, Dennie V., Jr, Jost, Lorenz, Keilholz, Ulrich, Khan, Saad, Kiss, Alexander, Köhne, Claus-Henning, Kunstfeld, Rainer, Lenz, H.einz-Josef, Lichtman, Stuart, Licitra, Lisa, Lion, Thomas, Litière, Saskia, Liu, Lifang, Loehrer, Patrick J., Markham, Merry Jennifer, Markman, Ben, Mayerhoefer, Marius, Meran, Johannes G., Michielin, Olivier, Moser, Elizabeth Charlotte, Mountzios, Giannis, Moynihan, Timothy, Nielsen, Torsten, Ohe, Yuichiro, Öberg, Kjell, Palumbo, Antonio, Peccatori, Fedro Alessandro, Pfeilstöcker, Michael, Raut, Chandrajit, Remick, Scot C., Robson, Mark, Rutkowski, Piotr, Salgado, Roberto, Schapira, Lidia, Schernhammer, Eva, Schlumberger, Martin, Schmoll, Hans-Joachim, Schnipper, Lowell, Sessa, Cristiana, Shapiro, Charles L., Steele, Julie, Sternberg, Cora N., Stiefel, Friedrich, Strasser, Florian, Stupp, Roger, Sullivan, Richard, Tabernero, Josep, Travado, Luzia, Verheij, Marcel, Voest, Emile, Vokes, Everett, Von Roenn, Jamie, Weber, Jeffrey S., Wildiers, Hans, and Yarden, Yosef

Published
2016
Full Text
View/download PDF

24. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

Author

Dupuis, Jehan, Morschhauser, Franck, Ghesquières, Hervé, Tilly, Hervé, Casasnovas, Olivier, Thieblemont, Catherine, Ribrag, Vincent, Bossard, Céline, Bras, Fabien Le, Bachy, Emmanuel, Hivert, Bénédicte, Nicolas-Virelizier, Emmanuelle, Jardin, Fabrice, Bastie, Jean-Noel, Amorim, Sandy, Lazarovici, Julien, Martin, Antoine, and Coiffier, Bertrand

Published
2015
Full Text
View/download PDF

31. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

Author

Pettengell, Ruth, Coiffier, Bertrand, Narayanan, Geetha, de Mendoza, Fernando Hurtado, Digumarti, Raghunadharao, Gomez, Henry, Zinzani, Pier Luigi, Schiller, Gary, Rizzieri, David, Boland, Giles, Cernohous, Paul, Wang, Lixia, Kuepfer, Christine, Gorbatchevsky, Igor, and Singer, Jack W

Published
2012
Full Text
View/download PDF

33. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Author

Récher, Christian, Coiffier, Bertrand, Haioun, Corinne, Molina, Thierry Jo, Fermé, Christophe, Casasnovas, Olivier, Thiéblemont, Catherine, Bosly, André, Laurent, Guy, Morschhauser, Franck, Ghesquières, Hervé, Jardin, Fabrice, Bologna, Serge, Fruchart, Christophe, Corront, Bernadette, Gabarre, Jean, Bonnet, Christophe, Janvier, Maud, Canioni, Danielle, Jais, Jean-Philippe, Salles, Gilles, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

34. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project

Author

Delabie, Jan, Holte, Harald, Vose, Julie M., Ullrich, Fred, Jaffe, Elaine S., Savage, Kerry J., Connors, Joseph M., Rimsza, Lisa, Harris, Nancy L., Müller-Hermelink, Konrad, Rüdiger, Thomas, Coiffier, Bertrand, Gascoyne, Randy D., Berger, Françoise, Tobinai, Kensei, Au, Wing Y., Liang, Raymond, Montserrat, Emili, Hochberg, Ephraim P., Pileri, Stefano, Federico, Massimo, Nathwani, Bharat, Armitage, James O., and Weisenburger, Dennis D.

Published
2011
Full Text
View/download PDF

36. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffier, Bertrand, Le Gouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecht, Christian

Published
2011
Full Text
View/download PDF

37. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Author

Weisenburger, Dennis D., Savage, Kerry J., Harris, Nancy Lee, Gascoyne, Randy D., Jaffe, Elaine S., MacLennan, Kenneth A., Rüdiger, Thomas, Pileri, Stefano, Nakamura, Shigeo, Nathwani, Bharat, Campo, Elias, Berger, Francoise, Coiffier, Bertrand, Kim, Won-Seog, Holte, Harald, Federico, Massimo, Au, Wing Y., Tobinai, Kensei, Armitage, James O., and Vose, Julie M.

Published
2011
Full Text
View/download PDF

38. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Author

Coiffier, Bertrand, Osmanov, Evgenii A, Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A, and Zinzani, Pier Luigi

Published
2011
Full Text
View/download PDF

39. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Author

Peyrade, Frédéric, Jardin, Fabrice, Thieblemont, Catherine, Thyss, Antoine, Emile, Jean-François, Castaigne, Sylvie, Coiffier, Bertrand, Haioun, Corinne, Bologna, Serge, Fitoussi, Olivier, Lepeu, Gérard, Fruchart, Christophe, Bordessoule, Dominique, Blanc, Michel, Delarue, Richard, Janvier, Maud, Salles, Bruno, André, Marc, Fournier, Marion, Gaulard, Philippe, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

40. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Author

Salles, Gilles, Seymour, John Francis, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Feugier, Pierre, Bouabdallah, Réda, Catalano, John Vincent, Brice, Pauline, Caballero, Dolores, Haioun, Corinne, Pedersen, Lars Moller, Delmer, Alain, Simpson, David, Leppa, Sirpa, Soubeyran, Pierre, Hagenbeek, Anton, Casasnovas, Olivier, Intragumtornchai, Tanin, Fermé, Christophe, da Silva, Maria Gomes, Sebban, Catherine, Lister, Andrew, Estell, Jane A, Milone, Gustavo, Sonet, Anne, Mendila, Myriam, Coiffier, Bertrand, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

43. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Author

Coiffier, Bertrand, Thieblemont, Catherine, de Guibert, Sophie, Dupuis, Jehan, Ribrag, Vincent, Bouabdallah, Réda, Morschhauser, Franck, Navarro, Robert, Le Gouill, Steven, Haioun, Corinne, Houot, Roch, Casasnovas, Olivier, Holte, Harald, Lamy, Thierry, Broussais, Florence, Payrard, Sandrine, Hatteville, Laurence, and Tilly, Hervé

Published
2016
Full Text
View/download PDF

44. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Author

Coiffier, Bertrand, Thieblemont, Catherine, Van Den Neste, Eric, Lepeu, Gérard, Plantier, Isabelle, Castaigne, Sylvie, Lefort, Sophie, Marit, Gérald, Macro, Margaret, Sebban, Catherine, Belhadj, Karim, Bordessoule, Dominique, Fermé, Christophe, and Tilly, Hervé

Published
2010
Full Text
View/download PDF

45. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study

Author

Jardin, Fabrice, Jais, Jean-Philippe, Molina, Thierry-Jo, Parmentier, Françoise, Picquenot, Jean-Michel, Ruminy, Philippe, Tilly, Hervé, Bastard, Christian, Salles, Gilles-André, Feugier, Pierre, Thieblemont, Catherine, Gisselbrecht, Christian, de Reynies, Aurelien, Coiffier, Bertrand, Haioun, Corinne, and Leroy, Karen

Published
2010
Full Text
View/download PDF

47. Supplement to: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Author

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., Hallek, Michael, and OʼBrien, Susan M.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results